In today's world, JWH-366 has become a topic of relevance and general interest for a wide spectrum of society. From politics to science, through culture and technology, JWH-366 has impacted our daily lives in various ways. There are many perspectives from which JWH-366 can be approached, and each of them offers a fascinating and constantly evolving panorama. In this article, we will explore some of the most important dimensions of JWH-366, analyzing its impact in different areas and its projection into the future.
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C25H24N2O |
| Molar mass | 368.480 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
JWH-366 (naphthalen-1-yl-(1-pentyl-5-pyridin-3-ylpyrrol-3-yl)methanone) is a synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the CB1 (Ki = 191 ± 12nM) and CB2 (Ki = 24 ± 1nM) receptors, with a strong (~8x) selectivity for the CB2 receptor over the CB1 receptor. JWH-366 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB1 receptor.[1]
In the United States JWH-366 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-366.[2][3][4][5]
In Canada, JWH-366 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.
In the United Kingdom, JWH-366 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.